OX26/CTX-conjugated PEGylated liposome as a dual-targeting gene delivery system for brain glioma

Molecular Cancer

Volumn 13, Issue 1, 2014, Pages

  Yue, Pei Jian ^a   He, Lei ^a   Qiu, Shu Wei ^a   Li, Yi ^a   Liao, Yi Ji ^b   Li, Xiang Pen ^a   Xie, Dan ^b   Peng, Ying ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Blood brain barrier; Chlorotoxin; Dual targeting; Gene therapy; Glioma

Indexed keywords

ANTINEOPLASTIC AGENT; CHLOROTOXIN; LIPOSOME; MACROGOL; OX 26; PC27 PEPTIDE; PLASMID DNA; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY; SCORPION VENOM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CANCER GENE THERAPY; CANCER SIZE; CELLULAR DISTRIBUTION; CYTOTOXICITY; DRUG EFFICACY; EVAPORATION; FLOW CYTOMETRY; GENE DELIVERY SYSTEM; GENE EXPRESSION; GLIOMA; HEK293 CELL LINE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; RAT; SURVIVAL TIME; ZETA POTENTIAL; ANIMAL; BRAIN TUMOR; CELL SURVIVAL; GENE TRANSFER; GENETIC TRANSFECTION; METABOLISM; PATHOLOGY; PLASMID; STATIC ELECTRICITY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE; WESTERN BLOTTING; WISTAR RAT;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; GENE TRANSFER TECHNIQUES; GLIOMA; HEK293 CELLS; HUMANS; LIPOSOMES; MALE; PARTICLE SIZE; PLASMIDS; RATS, WISTAR; SCORPION VENOMS; STATIC ELECTRICITY; TRANSFECTION;

EID: 84908102563     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-13-191     Document Type: Article

References (53)

1. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet 2012, 379:1984-1996.
2. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007, 114:97-109.
3. Pardridge WM. BBB-genomics: creating new openings for brain-drug targeting. Drug Discov Today 2001, 6:381-383.
4. Arko L, Katsyv I, Park GE, Luan WP, Park JK. Experimental approaches for the treatment of malignant gliomas. Pharmacol Ther 2010, 128:1-36.
5. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
6. Huwyler J, Wu D, Pardridge WM. Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci U S A 1996, 93:14164-14169.
7. Abu Lila AS, Ishida T, Kiwada H. Targeting anticancer drugs to tumor vasculature using cationic liposomes. Pharm Res 2010, 27:1171-1183.
8. Sapra P, Allen TM. Ligand-targeted liposomal anticancer drugs. Prog Lipid Res 2003, 42:439-462.
9. Hu Y, Xie J, Tong YW, Wang CH. Effect of PEG conformation and particle size on the cellular uptake efficiency of nanoparticles with the HepG2 cells. J Control Release 2007, 118:7-17.
10. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, Baselga J, Shao Y, Nielsen UB, Marks JD, Moore D, Papahadjopoulos D, Benz CC. Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 2002, 8:1172-1181.
11. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science 2004, 303:1818-1822.
12. Mukthavaram R, Jiang P, Saklecha R, Simberg D, Bharati IS, Nomura N, Chao Y, Pastorino S, Pingle SC, Fogal V, Wrasidlo W, Makale M, Kesari S. High-efficiency liposomal encapsulation of a tyrosine kinase inhibitor leads to improved in vivo toxicity and tumor response profile. Int J Nanomedicine 2013, 8:3991-4006.
13. Shi N, Boado RJ, Pardridge WM. Receptor-mediated gene targeting to tissues in vivo following intravenous administration of pegylated immunoliposomes. Pharm Res 2001, 18:1091-1095.
14. Ying X, Wen H, Lu WL, Du J, Guo J, Tian W, Men Y, Zhang Y, Li RJ, Yang TY, Shang DW, Lou JN, Zhang LR, Zhang Q. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release 2010, 141:183-192.
15. Ren J, Shen S, Wang D, Xi Z, Guo L, Pang Z, Qian Y, Sun X, Jiang X. The targeted delivery of anticancer drugs to brain glioma by PEGylated oxidized multi-walled carbon nanotubes modified with angiopep-2. Biomaterials 2012, 33:3324-3333.
16. Liang B, He ML, Chan CY, Chen YC, Li XP, Li Y, Zheng D, Lin MC, Kung HF, Shuai XT, Peng Y. The use of folate-PEG-grafted-hybranched-PEI nonviral vector for the inhibition of glioma growth in the rat. Biomaterials 2009, 30:4014-4020.
17. Shi N, Pardridge WM. Noninvasive gene targeting to the brain. Proc Natl Acad Sci U S A 2000, 97:7567-7572.
18. Zhang Y, Jeong Lee H, Boado RJ, Pardridge WM. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J Gene Med 2002, 4:183-194.
19. Pardridge WM, Buciak JL, Friden PM. Selective transport of an anti-transferrin receptor antibody through the blood-brain barrier in vivo. J Pharmacol Exp Ther 1991, 259:66-70.
20. Jefferies WA, Brandon MR, Hunt SV, Williams AF, Gatter KC, Mason DY. Transferrin receptor on endothelium of brain capillaries. Nature 1984, 312:162-163.
21. Wu D, Song BW, Vinters HV, Pardridge WM. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J Drug Target 2002, 10:239-245.
22. Yoon DJ, Chu DS, Ng CW, Pham EA, Mason AB, Hudson DM, Smith VC, MacGillivray RT, Kamei DT. Genetically engineering transferrin to improve its in vitro ability to deliver cytotoxins. J Control Release 2009, 133:178-184.
23. Deshane J, Garner CC, Sontheimer H. Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 2003, 278:4135-4144.
24. Lyons SA, O'Neal J, Sontheimer H. Chlorotoxin, a scorpion-derived peptide, specifically binds to gliomas and tumors of neuroectodermal origin. Glia 2002, 39:162-173.
25. Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, Ravanpay AC, Stroud MR, Kusuma Y, Hansen SJ, Kwok D, Munoz NM, Sze RW, Grady WM, Greenberg NM, Ellenbogen RG, Olson JM. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res 2007, 67:6882-6888.
26. Sun C, Veiseh O, Gunn J, Fang C, Hansen S, Lee D, Sze R, Ellenbogen RG, Olson J, Zhang M. In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. Small 2008, 4:372-379.
27. Veiseh O, Kievit FM, Gunn JW, Ratner BD, Zhang M. A ligand-mediated nanovector for targeted gene delivery and transfection in cancer cells. Biomaterials 2009, 30:649-657.
28. Huang JJ, Lin MC, Bai YX, Jing DD, Wong BC, Han SW, Lin J, Xu B, Huang CF, Kung HF. Ectopic expression of a COOH-terminal fragment of the human telomerase reverse transcriptase leads to telomere dysfunction and reduction of growth and tumorigenicity in HeLa cells. Cancer Res 2002, 62:3226-3232.
29. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum Mol Genet 2001, 10:677-685.
30. Huo LF, Tang JW, Huang JJ, Huang PT, Huang CF, Kung HF, Lin MC. Cancer immunotherapy targeting the telomerase reverse transcriptase. Cell Mol Immunol 2006, 3:1-11.
31. Pardridge WM. Blood-brain barrier delivery. Drug Discov Today 2007, 12:54-61.
32. Gao JQ, Lv Q, Li LM, Tang XJ, Li FZ, Hu YL, Han M. Glioma targeting and blood-brain barrier penetration by dual-targeting doxorubincin liposomes. Biomaterials 2013, 34:5628-5639.
33. Zhang P, Hu L, Yin Q, Zhang Z, Feng L, Li Y. Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation. J Control Release 2012, 159:429-434.
34. Shao K, Wu J, Chen Z, Huang S, Li J, Ye L, Lou J, Zhu L, Jiang C. A brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infection. Biomaterials 2012, 33:6898-6907.
35. Kaur IP, Bhandari R, Bhandari S, Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008, 127:97-109.
36. Qin Y, Chen H, Yuan W, Kuai R, Zhang Q, Xie F, Zhang L, Zhang Z, Liu J, He Q. Liposome formulated with TAT-modified cholesterol for enhancing the brain delivery. Int J Pharm 2011, 419:85-95.
37. Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Mol Pharm 2008, 5:496-504.
38. Simoes S, Filipe A, Faneca H, Mano M, Penacho N, Duzgunes N, de Lima MP. Cationic liposomes for gene delivery. Expert Opin Drug Deliv 2005, 2:237-254.
39. Zhang JS, Liu F, Huang L. Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity. Adv Drug Deliv Rev 2005, 57:689-698.
40. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 2009, 71:251-256.
41. Du J, Lu WL, Ying X, Liu Y, Du P, Tian W, Men Y, Guo J, Zhang Y, Li RJ, Zhou J, Lou JN, Wang JC, Zhang X, Zhang Q. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood-brain barrier and survival of brain tumor-bearing animals. Mol Pharm 2009, 6:905-917.
42. Jain S, Mishra V, Singh P, Dubey PK, Saraf DK, Vyas SP. RGD-anchored magnetic liposomes for monocytes/neutrophils-mediated brain targeting. Int J Pharm 2003, 261:43-55.
43. Szoka F, Papahadjopoulos D. Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. Proc Natl Acad Sci U S A 1978, 75:4194-4198.
44. Yang S, Chen J, Zhao D, Han D, Chen X. Comparative study on preparative methods of DC-Chol/DOPE liposomes and formulation optimization by determining encapsulation efficiency. Int J Pharm 2012, 434:155-160.
45. Shi N, Zhang Y, Zhu C, Boado RJ, Pardridge WM. Brain-specific expression of an exogenous gene after i.v. administration. Proc Natl Acad Sci U S A 2001, 98:12754-12759.
46. Pang Z, Lu W, Gao H, Hu K, Chen J, Zhang C, Gao X, Jiang X, Zhu C. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release 2008, 128:120-127.
47. Jones LJ, Haugland RP, Singer VL. Development and characterization of the NanoOrange protein quantitation assay: a fluorescence-based assay of proteins in solution. Biotechniques 2003, 34:850-854. 856, 858 passim.
48. Xin H, Jiang X, Gu J, Sha X, Chen L, Law K, Chen Y, Wang X, Jiang Y, Fang X. Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials 2011, 32:4293-4305.
49. Rivest V, Phivilay A, Julien C, Belanger S, Tremblay C, Emond V, Calon F. Novel liposomal formulation for targeted gene delivery. Pharm Res 2007, 24:981-990.
50. Li Y, He H, Jia X, Lu WL, Lou J, Wei Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials 2012, 33:3899-3908.
51. Qian Y, Zha Y, Feng B, Pang Z, Zhang B, Sun X, Ren J, Zhang C, Shao X, Zhang Q, Jiang X. PEGylated poly(2-(dimethylamino) ethyl methacrylate)/DNA polyplex micelles decorated with phage-displayed TGN peptide for brain-targeted gene delivery. Biomaterials 2013, 34:2117-2129.
52. Cai MY, Zhang B, He WP, Yang GF, Rao HL, Rao ZY, Wu QL, Guan XY, Kung HF, Zeng YX, Xie D. Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 2010, 101:1543-1549.
53. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecol Oncol 2005, 98:396-402.